StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Investment analysts at StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. Royal Bank of Canada cut their target price on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research note on Friday, October 25th. EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a report on Monday, September 23rd. Truist Financial cut shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Finally, Jefferies Financial Group restated a “hold” rating and set a $0.50 price target (down from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Nine investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Trading Down 2.1 %

Shares of NASDAQ:MRNS opened at $0.24 on Friday. The firm’s 50 day moving average is $0.57 and its two-hundred day moving average is $1.13. The firm has a market capitalization of $13.16 million, a P/E ratio of -0.10 and a beta of 1.25. Marinus Pharmaceuticals has a 52 week low of $0.23 and a 52 week high of $11.26.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Point72 DIFC Ltd bought a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter worth approximately $28,000. SG Americas Securities LLC acquired a new position in Marinus Pharmaceuticals in the second quarter worth approximately $34,000. AQR Capital Management LLC increased its holdings in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at $64,000. Finally, World Investment Advisors LLC acquired a new stake in shares of Marinus Pharmaceuticals during the 3rd quarter valued at $104,000. 98.80% of the stock is owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.